X4 and taiba to distribute WHIM syndrome therapy in Middle East

X4 has entered an exclusive agreement with taiba rare for distributing and commercialising Xolremdi in select Middle Eastern countries.

Feb 21, 2025 - 06:00

X4 and taiba to distribute WHIM syndrome therapy in Middle East

X4 has entered an exclusive agreement with taiba rare for distributing and commercialising Xolremdi in select Middle Eastern countries.

Read the original article

Tags:

Previous Article

Zealand Pharma steadfastly upholds amylin-based obesity drug strategy

Key pharma launch trends in 2024

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

StromaForte by Swedish StromaBio for Ageing: Likelihood...

Nov 6, 2023

STAT+: Intellia plays down concerns about accidental germline transmission in CRISPR trial

STAT+: Intellia plays down concerns about accidental ge...

Aug 21, 2023

STAT+: Eli Lilly, riding a hot streak, expects to double planned employment in Boston research center

STAT+: Eli Lilly, riding a hot streak, expects to doubl...

Oct 20, 2023